After guideline changes, aspirin use dropped off overall, even for higher-risk patients in whom it might still be considered.

Underrepresentation of women as participants and researchers in CV clinical trials remains a problem, asserts a review ...

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

While intensity didn’t appear to matter in this network meta-analysis, location did: in-person programs had the most impact.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

A study comparing men and women suggests much of the association arises from genetic propensity to both conditions.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

In a field rife with disagreement, STS, AATS, and others say the European guidelines got it right when it comes to CABG.

Following the recent IDE Approval by the U.S. Food and Drug Administration (FDA) for MagicTouch PTA, this enrolment heralds ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Much has changed since the 2013 document came out, with new information on pacing devices, techniques, and more.